Document is current
Any future updates will be listed below
-
Authors
Roodhooft, I.
Kinget, L.
Mammone, G. https://orcid.org/0000-0001-8589-2148
Baldewijns, M.
Debruyne, PR https://orcid.org/0000-0001-5438-9697
Roussel, E.
Albersen, M.
Demeulenaere, O. https://orcid.org/0009-0006-5986-2221
Garg, AD https://orcid.org/0000-0002-9976-9922
Clement, PM
Van Loon, J.
De Vleeschouwer, S. https://orcid.org/0000-0002-9576-9917
Van Den Bulck, H.
Vandermeulen, H.
De Wever, L.
Laerte, A.
Beuselinck, B. https://orcid.org/0000-0001-7427-9102
-
Funding
Funding for this research was provided by:
Fonds voor Wetenschappelijk Onderzoek Vlaanderen
- License Information
-
More Information
Article History
Received: 2 September 2025
Revised: 21 January 2026
Accepted: 13 February 2026
First Online: 7 March 2026
Competing interests
: IR reports no conflicts of interest. LK reports no conflicts of interest. MB reports no conflicts of interest. ER reports no conflicts of interest. AG reports no conflicts of interest. PMC reports advisory board roles with MSD, BMS, Servier and Novocure. PRD reports advisory board roles with Astellas Pharma, Ipsen, MSD and travel support from Ipsen. He hold stocks in Mural Oncology PLC, UCB, and Biocartis Group NV. BB reports advisory board roles with MSD, BMS, and Ipsen. He was speaker for MSD, BMS, Ipsen and Pfizer and reports research funding for BMS. He has provided expert testimony for MSD. MA reports unrestricted grants from Astellas and MSD. ADG is editor-in-chief of Genes & Immunity.
